1550 related articles for article (PubMed ID: 29663292)
1. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
Fattah H; Vallon V
Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
3. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Vallon V
Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
5. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
Qiu H; Novikov A; Vallon V
Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
[TBL] [Abstract][Full Text] [Related]
6. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
7. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
8. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
9. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
11. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Lupsa BC; Inzucchi SE
Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
[TBL] [Abstract][Full Text] [Related]
12. Knockout of Na
Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
Perry RJ; Shulman GI
J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
[TBL] [Abstract][Full Text] [Related]
14. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
Xu B; Li S; Kang B; Zhou J
Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
Davidson JA
Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
[TBL] [Abstract][Full Text] [Related]
16. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Handelsman Y
Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibitors May Predispose to Ketoacidosis.
Taylor SI; Blau JE; Rother KI
J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
[TBL] [Abstract][Full Text] [Related]
18. Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering.
Ceylan AF; Ren SY
Curr Drug Targets; 2018; 19(9):1045-1050. PubMed ID: 29673309
[TBL] [Abstract][Full Text] [Related]
19. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
20. [NON-CARDIAL EFFECTS OF SGLT2 INHIBITORS (REVIEW)].
Doroshkevych I; Vozniuk L; Voloshchuk N; Klekot O; Kyrychenko O
Georgian Med News; 2018 Dec; (285):57-62. PubMed ID: 30702071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
